By Josh Beckerman
Shares of Moleculin Biotech pared earlier gains after the pharmaceutical company announced a $3.5 million registered direct offering and concurrent private placement.
The stock was recently up 14%, to $1.22, midday Tuesday. Shares had risen to an intraday high of $1.64 following Monday's withdrawal of a December filing for public offering of stock and warrants.
Volume was more than 33.4 million shares, compared with a 65-day average of 4.3 million.
The company said Tuesday afternoon that it entered an agreement with an institutional investor to sell 3.27 million shares or pre-funded warrants in lieu thereof, and 6.54 million warrants, at a combined price of $1.07 a share and accompanying warrants.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 25, 2025 13:09 ET (18:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.